{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"94"}],"units":"Participants"}],"description":"Survival rate of participants after completion of tandem transplant","groups":[{"description":"Tandem autologous hematopoietic stem cell transplantation with melphalan followed by melphalan and bortezomib in patients with multiple myeloma\n\nBortezomib: Bortezomib 1.6mg/m2 on day -4 and day -1","id":"OG000","title":"Tandem Transplantation With Melphalan and Bortezomib"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"94 participant survival assessed after completion of tandem transplant","reportingStatus":"POSTED","timeFrame":"3 years","title":"To Determine the Overall Survival of Patients With Multiple Myeloma Treated With High-dose Melphalan or High-dose Melphalan in Combination With Bortezomib Given in Tandem Transplants.","type":"SECONDARY","unitOfMeasure":"Participants"}